All UCLouvain articles
-
NewsStudy reveals how a live bacterial therapy reshapes the vaginal microbiome and identifies predictors of treatment success
A new study provides the most detailed picture yet of how a promising bacterial therapy works to prevent recurrent bacterial vaginosis (BV) and why it works better for some women than others.
-
News€20 million EIB venture debt financing to support microbiome research and development
The EIB has signed €20 million in venture debt financing with Belgian microbiome health company The Akkermansia Company to accelerate the R&D and commercial activities around the Akkermansia muciniphila bacterium.